Pfizer Research Grant Request for Proposals: Biochemical and Molecular Characterization of Marstacimab and TFPI Pathways
Pfizer offers grants for research on the molecular mechanisms of marstacimab and TFPI pathways to deepen understanding of coagulation biology.
Funder: Pfizer Inc.
Due Dates: July 1, 2026 (Full application)
Funding Amounts: Up to $50,000 USD per project (plus up to $50,000 USD in study drug); 1-year project period; total RFP budget $300,000 USD
Summary: Supports research into the biochemical and molecular mechanisms of marstacimab and TFPI pathways to advance understanding of coagulation biology.
Key Information: Applicants must be based in eligible countries; organizations only (not individuals); strict deadline—late applications not reviewed.
Description
This competitive grant program from Pfizer supports research aimed at elucidating the molecular and cellular mechanisms underlying marstacimab-TFPI interactions. Projects should advance foundational understanding of the interactions between marstacimab, anti-TFPI monoclonal antibodies, and tissue factor pathway inhibitor (TFPI) using innovative approaches in biochemistry, molecular biology, and related disciplines. Areas of interest include the basic biology of TFPI, the impact of differential TFPI expression within tissues, the role of various TFPI pools and isoforms in coagulation regulation, and the pharmacology of combined therapies involving anti-TFPI. The goal is to generate new insights into the regulation of coagulation and the biological functions of TFPI and marstacimab.
